» Articles » PMID: 33748283

Dilation of Brain Veins and Perivascular Infiltration by Glioblastoma Cells in an Assay of Early Tumor Angiogenesis

Abstract

The cranial window (CW) technique provides a simple and low-cost method to assess tumor angiogenesis in the brain. The CW combined with histology using selective markers for tumor and endothelial cells can allow a sensitive monitoring of novel antiangiogenesis therapies in preclinical models. The CW was established in cyclosporine immunosuppressed rats that were stereotactically grafted with fluorescent U87MG glioblastoma cells. One to 3 weeks after grafting, brain vasculature was visualized and assessed by immunofluorescence microscopy using antibodies against endothelial and smooth-muscle cells and blood brain barrier. At 1-2 weeks after grafting, the CW reliably detected the hypertrophy of venous-venous anastomoses and cortical veins. These structures increased highly significantly their pregrafting diameter. Arterialized veins and hemorrhages were seen by three weeks after grafting. Immunofluorescence microscopy showed significant branching and dilation of microvessels, particularly those surrounded by tumor cells. Mechanistically, these changes lead to loss of vascular resistance, increased venous outflow, and opening of venous-venous anastomoses on the cortical surface. Data from the present study, namely, the hypertrophy of cortical venous-venous anastomoses, microvessel branching, and dilation of the microvessels surrounded by tumor cells, indicate the power of this model for the sensitive monitoring of early tumor angiogenesis.

Citing Articles

Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.

Guida L, Stumpo V, Bellomo J, van Niftrik C, Sebok M, Berhouma M Cancers (Basel). 2022; 14(6).

PMID: 35326580 PMC: 8946242. DOI: 10.3390/cancers14061432.

References
1.
Falchetti M, DAlessandris Q, Pacioni S, Buccarelli M, Morgante L, Giannetti S . Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. Int J Cancer. 2018; 144(6):1331-1344. PMC: 6590500. DOI: 10.1002/ijc.31983. View

2.
Martini M, De Pascalis I, DAlessandris Q, Fiorentino V, Pierconti F, Marei H . VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. BMC Cancer. 2018; 18(1):553. PMC: 5946426. DOI: 10.1186/s12885-018-4442-2. View

3.
Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

4.
Stan A, Nemati M, Pietsch T, Walter G, Dietz H . In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg. 1995; 82(6):1044-52. DOI: 10.3171/jns.1995.82.6.1044. View

5.
Mathivet T, Bouleti C, Van Woensel M, Stanchi F, Verschuere T, Phng L . Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. EMBO Mol Med. 2017; 9(12):1629-1645. PMC: 5709745. DOI: 10.15252/emmm.201607445. View